XML 31 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities:      
Profit for the year $ 108,606 $ 130,717 $ 1,070
Adjustments for:      
Income tax expense 26,758 43,837 12,325
Depreciation 188,775 167,297 140,579
Amortization 2,265 1,631 1,293
Depreciation of right of use assets 63,339 49,199 40,820
(Gain) / loss from the disposal of other property items (3,718) 397 (2,198)
Gain from the sale of farmland and other assets 0 0 (2,064)
(Gain) / loss from the sale of subsidiary 0 (10) 554
Bargain purchase gain on acquisition (10,107) 0 0
Net loss/(gain)from the fair value adjustment of Investment properties 2,961 4,331 (1,077)
Equity settled share-based compensation granted 10,227 6,406 4,316
Loss from derivative financial instruments and forwards 13,685 17,276 10,058
Interest, finance cost related to lease liabilities and other financial expense, net 83,130 75,610 47,686
Initial recognition and changes in fair value of non-harvested biological assets (unrealized) (44,935) (11,310) (32,975)
Changes in net realizable value of agricultural produce after harvest (unrealized) (72) 4,001 481
Provision and allowances 999 1,146 1,940
Net loss / (gain) of inflation effects on the monetary items 2,144 (11,541) (12,064)
Foreign exchange (gains)/ losses, net (19,278) (18,939) 109,266
Cash flow hedge – transfer from equity 40,195 52,650 24,363
Subtotal 464,974 512,698 344,373
Changes in operating assets and liabilities:      
Increase in trade and other receivables (60,753) (40,449) (55,233)
Decrease / (increase) in inventories 45,437 (102,815) (30,165)
(Increase) / decrease in biological assets (3,686) 7,597 (10,290)
Increase in other assets (1,056) (303) (35)
(Increase) / Decrease in derivative financial instruments (9,661) (29,319) 5,234
(Decrease) / Increase in trade and other payables (64,502) (1,499) 828
Increase in payroll and social security liabilities 7,681 4,874 4,120
(Decrease) / increase in provisions for other liabilities (290) 74 380
Net cash generated from operating activities before taxes paid 378,144 350,858 259,212
Income tax paid (8,118) (2,196) (2,087)
Net cash generated from operating activities [1] 370,026 348,662 257,125
Cash flows from investing activities:      
Acquisition of business, net of cash and cash equivalents acquired 1,120 0 0
Purchases of property, plant and equipment (217,776) (199,295) (168,529)
Purchase of cattle and non-current biological assets (9,096) (11,776) (7,339)
Purchases of intangible assets (3,350) (1,934) (1,122)
Interest received and others 5,199 16,729 25,421
Proceeds from disposal of other property items 2,770 2,946 3,482
Proceeds from the sale of farmland and other assets 9,879 8,099 16,022
Proceeds from the sale of subsidiary 10,000 10,010 10,149
Acquisition of short-term investment (98,010) 0 0
Net cash used in investing activities [2] (299,264) (175,221) (121,916)
Cash flows from financing activities:      
Proceeds from long-term borrowings 41,082 30,972 116,015
Payments of long-term borrowings (14,012) (108,425) (34,750)
Proceeds from short-term borrowings 347,928 286,115 207,217
Payments of short-term borrowings (192,648) (328,463) (233,540)
Interest paid [3] (44,788) (53,587) (60,026)
Borrowings prepayment related expenses 0 (3,068) 0
Proceeds from exercise of employee share options 2,124 0 0
Collections / (Payments) of derivatives financial instruments 118 2,370 (1,687)
Lease payments (91,175) (62,273) (40,336)
Purchase of own shares (36,844) (66,463) (4,365)
Dividends paid to non-controlling interest (358) (311) (2,447)
Dividends paid to shareholders (35,000) 0 0
Net cash used from financing activities [4] (23,573) (303,133) (53,919)
Net increase / (decrease) in cash and cash equivalents 47,189 (129,692) 81,290
Cash and cash equivalents at beginning of year 199,766 336,282 290,276
Effect of exchange rate changes and inflation on cash and cash equivalents [5] (16,302) (6,824) (35,284)
Cash and cash equivalents at end of year $ 230,653 $ 199,766 $ 336,282
[1] Includes (38,043), (30,666) and (14,956) of the combined effect of IAS 29 and IAS 21 of the Argentine subsidiaries for 2022, 2021 and 2020, respectively.
[2] Includes (83), (4,694) and (429) of the combined effect of IAS 29 and IAS 21 of the Argentine subsidiaries for 2022, 2021 and 2020, respectively.
[3] Includes 77, (1,109) and (1,639) of the combined effect of IAS 29 and IAS 21 of the Argentine subsidiaries for 2022, 2021 and 2020, respectively.
[4] Includes 45,359, 41,238 and 15,694 of the combined effect of IAS 29 and IAS 21 of the Argentine subsidiaries for 2022, 2021 and 2020, respectively.
[5] Includes (7,233), (5,878) and (309) of the combined effect of IAS 29 and IAS 21 of the Argentine subsidiaries for 2022, 2021 and 2020, respectively.